Searched for
SCLEROSIS TREATMENT DRUG
US Stocks: Apellis shares double on Biogen's $5.6 billion buyout planBiogen will buy Apellis Pharmaceuticals for about $5.6 billion, adding a promising kidney disease drug to broaden its rare-disease portfoli...- Biocon arm gets USFDA nod for generic Everolimus tabletsBiocon's arm, Biocon Pharma Ltd, has secured USFDA approval for its generic Everolimus tablets. This medication aids in treating tuberous s...
- Lupin gets USFDA nod for multiple sclerosis drugDrug maker Lupin has secured approval from the US health regulator for its generic multiple sclerosis treatment. The company received tenta...
- Zydus ties up with Synthon BV for multiple sclerosis drug launch in USZydus Lifesciences will launch a generic drug for multiple sclerosis in the United States. This is through a partnership with Synthon BV. T...
- Zydus receives USFDA Orphan Drug Designation for Usnoflast to treat ALSZydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Usnoflast, a novel oral NLRP3 inhibitor, for treating amyotr...
- Roche Pharma launches multiple sclerosis treatment drug in IndiaThe company has introduced Ocrevus (Ocrelizumab) which is the first and only approved disease modifying therapy for both Relapsing Remittin...
- Scientists discover a genetic variant linked to severity of multiple sclerosisScientists have identified a genetic variant that is linked to the severity of multiple sclerosis (MS) and the progression of the disease o...
- Can harnessing the brain’s immune cells avert Alzheimer's? This is what researchers thinkMost available treatments target just one of the multiple processes.
- Zydus Cadila gets tentative USFDA nod to market generic sclerosis treatment drugDrug firm Zydus Cadila on Thursday said it has received tentative approval from the US health regulator to market Fingolimod capsules, used...
- Glenmark gets tentative nod from USFDA for generic multiple sclerosis treatment drugThese are generic version of Tecfidera Capsules, 120 mg and 240 mg, of Biogen Inc.
- Sun Pharma settles patent litigation with Acorda TherapeuticsSun Pharma has settled patent litigation with Acorda Therapeutics over Ampyra extended-release tablets, which is used in the treatment of m...
- Biogen Idec gets DCGI nod for multiple sclerosis oral drugThe company has received approval for the first oral therapy drug Tecfidera for multiple sclerosis by DCGI, Biogen Idec Biotech India Pvt L...
- Natco Pharma up 20%, hits 52-week high on favourable ruling on Copaxone in USNatco Pharma was locked in at upper circuit at Rs 588.10, up 20 per cent. The stock hit a low of Rs 540 in trade today.
- Natco Pharma gets favourable ruling for generic Copaxone in USNatco Pharma on Saturday said it has obtained a favourable ruling from a US Court that paves way for launch of generic Copaxone.
- USFDA gives nod for Riluzole tablets to Sun Pharma, GlenmarkSun Pharma and Glenmark have got approval from US health regulator to sell generic versions of nervous system disorder treatment drug Riluz...
- Glenmark gets USFDA approval for sclerosis treatment drugDrug firm Glenmark Pharmaceuticals today said it has received US health regulator's approval to market Riluzole tablets.
- Biocon to launch psoriasis drug novel biologic in JulyThe company had received marketing authorisation for Itolizumab from the Drugs Controller General of India (DCGI) in January, 2013.
- Biocon gets DCGI approval to market anti-psoriasis drug, Itolizumab"The company has received market authorisation from the DCGI for its novel biologic Itolizumab, for treatment of chronic plaque psoriasis,"...
- Natco Pharma loses patent case against Teva Pharmaceutical Industries of anti-sclerosis drugNatco Pharma has lost a patent litigation against Israel's Teva Pharmaceutical Industries in the US over multiple sclerosis treatment drug,...
- Glenmark gets USFDA's tentative nod for RiluzoneGlenmark Generics, a subsidiary of Glenmark Pharmaceuticals, today said it has received tentative approval from the USFDA for generic versi...
Load More
